تقرير
Oncogenic osteomalacia illustrating the effect of fibroblast growth factor 23 on phosphate homeostasis.
| العنوان: | Oncogenic osteomalacia illustrating the effect of fibroblast growth factor 23 on phosphate homeostasis. |
|---|---|
| المؤلفون: | Westerberg PA; Department of Medical Sciences, Uppsala University, Uppsala, Sweden., Linde T; Department of Medical Sciences, Uppsala University, Uppsala, Sweden., Vanderschueren D; Laboratory of diagnostic medicine, Katholieke Universiteit Leuven, Leuven, Belgium ; laboratory of experimental medicine and endocrinology, Katholieke Universiteit Leuven, Leuven, Belgium., Billen J; Laboratory of diagnostic medicine, Katholieke Universiteit Leuven, Leuven, Belgium ; laboratory of experimental medicine and endocrinology, Katholieke Universiteit Leuven, Leuven, Belgium., Jans I; Laboratory of diagnostic medicine, Katholieke Universiteit Leuven, Leuven, Belgium ; laboratory of experimental medicine and endocrinology, Katholieke Universiteit Leuven, Leuven, Belgium., Ljunggren Ö; Department of Medical Sciences, Uppsala University, Uppsala, Sweden. |
| المصدر: | Clinical kidney journal [Clin Kidney J] 2012 Jun; Vol. 5 (3), pp. 240-3. Date of Electronic Publication: 2012 Mar 29. |
| نوع المنشور: | Case Reports |
| اللغة: | English |
| بيانات الدورية: | Publisher: Oxford University Press Country of Publication: England NLM ID: 101579321 Publication Model: Print-Electronic Cited Medium: Print ISSN: 2048-8505 (Print) Linking ISSN: 20488505 NLM ISO Abbreviation: Clin Kidney J Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: Oxford : Oxford University Press |
| مستخلص: | In oncogenic osteomalacia (OOM), fibroblast growth factor 23 (FGF23) induces renal phosphate wasting and inhibits the appropriate increase of calcitriol. A patient suffering from OOM is described. Serum calcium, phosphate, biointact parathyroid hormone and intact FGF23 as well as the calcitriol and 24,25-vitamin D levels were measured before and after tumour removal. The clinical approach to a patient with hypophosphataemia is discussed and the changes in mineral metabolism after removal of a FGF23-producing tumour are described. |
| References: | Nat Genet. 2000 Nov;26(3):345-8. (PMID: 11062477) Kidney Int. 2010 Sep;78(5):463-72. (PMID: 20531451) J Clin Invest. 1984 Jun;73(6):1580-9. (PMID: 6547151) Bone. 2008 Jun;42(6):1235-9. (PMID: 18396126) Endocr Relat Cancer. 2011 Jun 08;18(3):R53-77. (PMID: 21490240) J Clin Endocrinol Metab. 2010 Apr;95(4):1846-50. (PMID: 20157195) J Clin Endocrinol Metab. 2002 Nov;87(11):4957-60. (PMID: 12414858) Am J Surg Pathol. 2004 Jan;28(1):1-30. (PMID: 14707860) N Engl J Med. 2003 Apr 24;348(17):1656-63. (PMID: 12711740) N Engl J Med. 2010 Mar 25;362(12):1102-9. (PMID: 20335586) J Bone Miner Res. 2009 Nov;24(11):1879-88. (PMID: 19419316) Am J Hum Genet. 2006 Feb;78(2):179-92. (PMID: 16358214) J Bone Miner Metab. 2012 Jan;30(1):1-9. (PMID: 22167381) Curr Opin Nephrol Hypertens. 2011 Jul;20(4):337-44. (PMID: 21610497) Eur J Mass Spectrom (Chichester). 2010;16(1):81-9. (PMID: 20065517) J Clin Invest. 1986 Jan;77(1):7-12. (PMID: 3753709) Curr Opin Nephrol Hypertens. 2008 Jul;17(4):363-7. (PMID: 18660671) Am J Kidney Dis. 2012 Jan;59(1):152-9. (PMID: 22075221) |
| فهرسة مساهمة: | Keywords: FGF23; mineral metabolism; osteomalacia; phosphate |
| تواريخ الأحداث: | Date Created: 20150613 Date Completed: 20150613 Latest Revision: 20200930 |
| رمز التحديث: | 20240829 |
| مُعرف محوري في PubMed: | PMC4400509 |
| DOI: | 10.1093/ckj/sfs031 |
| PMID: | 26069775 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 2048-8505 |
|---|---|
| DOI: | 10.1093/ckj/sfs031 |